iCell Gene Therapeutics

Quick facts

Phase 1 pipeline

• anti-CD5 CAR T cells
• BCMA-CD19 cCAR T cells
• BCMA-CS1 cCAR T cells
• CD123-CD33 cCAR T cells
• CD19 CARvac T cells
• CD20-CD19 cCAR T cells
• CD4 CAR T cells
• CD7 CAR T cells
• CD7CAR T cells
• CLL1-CD33 cCAR T cells

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• iCell Gene Therapeutics portfolio CI brief
• iCell Gene Therapeutics pipeline updates RSS